Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI study 1182.51)

Journal of Acquired Immune Deficiency Syndromes

Volumn 47, Issue 4, 2008, Pages 429-440

  Walmsley, Sharon L ^a   Katlama, Christine ^b   Lazzarin, Adriano ^c   Arestéh, Keikawus ^d   Pierone, Gerald ^e   Blick, Gary ^f   Johnson, Margaret ^g   Meier, Ulrich ^h   MacGregor, Thomas R ⁱ   Leith, Johnathan G ^j  

^a UNIVERSITY OF TORONTO   (Canada)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d Vivantes Auguste Viktoria Klinikum   (Germany)

^e Treasure Coast Infectious Disease Consultants   (United States)

^f Circle Medical ^*  (United States)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

ⁱ BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^j BOEHRINGER INGELHEIM CANADA LTD   (Canada)

more..

Author keywords

Combination antiretroviral therapy; Dual boosted protease inhibitor regimen; Nonpeptidic; Protease inhibitors; Tipranavir

Indexed keywords

AMPRENAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FLATULENCE; GASTROINTESTINAL DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LOOSE FECES; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NUTRITIONAL DISORDER; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; VOMITING;

EID: 40649122856     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318160a529     Document Type: Article

References (20)